Primary or Recurrent Clostridioides Difficile Infection Treatment With Capsules of Lyophilised Faecal Microbiota vs Fidaxomicin
A Randomised, Controlled, Open-label Phase III Clinical Trial in Patients With Primary or Recurrent Clostridioides Difficile (CD) Infection, to Evaluate the Efficacy and Safety of Capsules of Lyophilised Faecal Microbiota vs Fidaxomicin.
Sponsor: Mikrobiomik Healthcare Company S.L.
This PHASE3 trial investigates Primary Clostridium Difficile Infection and Recurrent Clostridium Difficile Infection and is currently completed. Mikrobiomik Healthcare Company S.L. leads this study, which shows 8 recorded versions since 2021 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Apr 2025 — Sep 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Apr 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Feb 2024 — Jul 2024 [monthly]
Completed PHASE3
Status: Recruiting → Completed
▶ Show 3 earlier versions
-
Dec 2022 — Feb 2024 [monthly]
Recruiting PHASE3
-
Jul 2022 — Dec 2022 [monthly]
Recruiting PHASE3
-
Feb 2022 — Jul 2022 [monthly]
Recruiting PHASE3
First recorded
Oct 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Mikrobiomik Healthcare Company S.L.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Alicante, Spain , Barakaldo, Spain , Barcelona, Spain , Bilbao, Spain , Córdoba, Spain , Donostia / San Sebastian, Spain , Girona, Spain , Logroño, Spain , Madrid, Spain , Palma de Mallorca, Spain and 4 more locations